Dear Loyal Reader, Paul here, passing along a message on an urgent opportunity for you… Within 48 hours, I plan to release a trade alert in my Extreme Fortunes research service that is on track to see 1,000% in the next three to five years. I've been a professional investor for over two decades — and some of the biggest gains I've made in my career have been in biotech. In Extreme Fortunes, one particular sector that's seen phenomenal success is biotech takeovers, which is when a company gets taken over by another. When these takeovers happen, these stocks can absolutely take off and rocket higher. Already, we've seen this happen multiple times — and it has led readers to make some of our best gains. Take a look at my tweet below where I listed them: This next biotech recommendation has the same potential as these stocks — and MORE. Not only does this company have a "first-pick" drug, but it's also weeks away from potentially receiving FDA approval. That alone could be a major catalyst for explosive profits! From my experience, it's the ones who get in on these stocks on the ground floor who benefit the most. Click here to subscribe to Extreme Fortunes within the next 24 hours! That way, you get all the details you need and get in on this trade before it goes live! Regards, Paul Mampilly Editor, Profits Unlimited (c) 2021 Banyan Hill Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 866-584-4096) Legal Notice The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: http://banyanhill.com/contact-us Remove your email from this list: Click here to Unsubscribe |
No comments:
Post a Comment